Published in Neuroimage on February 16, 2007
Nuclear imaging of neuroinflammation: a comprehensive review of [11C]PK11195 challengers. Eur J Nucl Med Mol Imaging (2008) 2.41
Optimization of supervised cluster analysis for extracting reference tissue input curves in (R)-[(11)C]PK11195 brain PET studies. J Cereb Blood Flow Metab (2012) 1.10
[18F]DPA-714: direct comparison with [11C]PK11195 in a model of cerebral ischemia in rats. PLoS One (2013) 1.00
Reduced parahippocampal and lateral temporal GABAA-[11C]flumazenil binding in major depression: preliminary results. Eur J Nucl Med Mol Imaging (2009) 0.90
[¹¹C]-(R)PK11195 tracer kinetics in the brain of glioma patients and a comparison of two referencing approaches. Eur J Nucl Med Mol Imaging (2013) 0.85
Pharmacokinetic Analysis of (64)Cu-ATSM Dynamic PET in Human Xenograft Tumors in Mice. Diagnostics (Basel) (2015) 0.75
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Mild cognitive impairment. Lancet (2006) 10.21
Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol (2010) 8.74
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging (2010) 7.82
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med (2006) 7.40
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA (2009) 7.29
Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol (2006) 6.97
Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. J Nucl Med (2004) 6.10
The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol (2010) 4.59
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet (2012) 3.73
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol (2009) 3.65
89Zr immuno-PET: comprehensive procedures for the production of 89Zr-labeled monoclonal antibodies. J Nucl Med (2003) 3.26
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol (2007) 3.22
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell (2012) 2.76
Performance of immuno-positron emission tomography with zirconium-89-labeled chimeric monoclonal antibody U36 in the detection of lymph node metastases in head and neck cancer patients. Clin Cancer Res (2006) 2.71
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging (2004) 2.58
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Cognitive impairment in heart failure: a systematic review of the literature. Eur J Heart Fail (2006) 2.56
Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol (2002) 2.56
Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol (2007) 2.48
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc (2007) 2.43
Midlife blood pressure and the risk of hippocampal atrophy: the Honolulu Asia Aging Study. Hypertension (2004) 2.43
Brain imaging in patients with diabetes: a systematic review. Diabetes Care (2006) 2.39
Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem (2009) 2.32
Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry (2008) 2.28
Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. Neurobiol Aging (2010) 2.27
Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.22
Frontotemporal dementia in The Netherlands: patient characteristics and prevalence estimates from a population-based study. Brain (2003) 2.20
Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele. Lancet Neurol (2010) 2.18
Whole brain resting-state analysis reveals decreased functional connectivity in major depression. Front Syst Neurosci (2010) 2.16
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging (2006) 2.08
Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology (2004) 2.00
Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement (2013) 1.98
Advances in the early detection of Alzheimer's disease. Nat Med (2004) 1.97
Impact of age-related cerebral white matter changes on the transition to disability -- the LADIS study: rationale, design and methodology. Neuroepidemiology (2005) 1.92
The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav (2014) 1.90
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Repeatability of 18F-FDG PET in a multicenter phase I study of patients with advanced gastrointestinal malignancies. J Nucl Med (2009) 1.88
Delta 9-tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology (2008) 1.88
Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol (2003) 1.86
Feelings of loneliness, but not social isolation, predict dementia onset: results from the Amsterdam Study of the Elderly (AMSTEL). J Neurol Neurosurg Psychiatry (2012) 1.84
Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp (2010) 1.83
Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol Aging (2008) 1.82
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Intrathecal chemokine synthesis in mild cognitive impairment and Alzheimer disease. Arch Neurol (2006) 1.79
Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med (2012) 1.78
Shining a light on posterior cortical atrophy. Alzheimers Dement (2012) 1.77
Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding. J Nucl Med (2009) 1.77
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Deficits of memory, executive functioning and attention following infarction in the thalamus; a study of 22 cases with localised lesions. Neuropsychologia (2003) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Radiation dosimetry of 89Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and neck cancer patients. J Nucl Med (2009) 1.68
Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET. J Cereb Blood Flow Metab (2006) 1.68
Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem (2004) 1.68
Reduced orbitofrontal-striatal activity on a reversal learning task in obsessive-compulsive disorder. Arch Gen Psychiatry (2006) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
A specific role of the human hippocampus in recall of temporal sequences. J Neurosci (2009) 1.66
Why gamblers fail to win: a review of cognitive and neuroimaging findings in pathological gambling. Neurosci Biobehav Rev (2009) 1.66
Alcohol use disorders and the course of depressive and anxiety disorders. Br J Psychiatry (2012) 1.66
Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators. BJU Int (2006) 1.65
Attentional bias and disinhibition toward gaming cues are related to problem gaming in male adolescents. J Adolesc Health (2011) 1.63
Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging (2011) 1.63
Stability of FDG-PET Radiomics features: an integrated analysis of test-retest and inter-observer variability. Acta Oncol (2013) 1.62
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Contribution of metabolic syndrome components to cognition in older individuals. Diabetes Care (2007) 1.61
Hyperaemic microvascular resistance is not increased in viable myocardium after chronic myocardial infarction. Eur Heart J (2007) 1.60
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Disorder-specific neuroanatomical correlates of attentional bias in obsessive-compulsive disorder, panic disorder, and hypochondriasis. Arch Gen Psychiatry (2005) 1.58
Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. Biol Psychiatry (2012) 1.58
Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. Arch Neurol (2007) 1.57
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Response perseveration and ventral prefrontal sensitivity to reward and punishment in male problem gamblers and smokers. Neuropsychopharmacology (2008) 1.56